| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | GDC-0449 | FIMM | pan-cancer | AAC | 0.025 | 0.9 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.018 | 0.9 |
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |